Peter Anastasiou Appointed Vice Chairman

27 August 2015, Melbourne, Australia: Immuron Limited (ASX:IMC) wishes to announce that current Non-Executive Director Mr Peter Anastasiou will assume the title of Vice Executive Chairman with immediate effect.

Over the past month Mr Anastasiou has had an increased level of involvement in the Company's activities, and his ongoing involvement is required to continue to facilitate the progression of the US market development opportunities, whilst supporting the Company's new Chief Executive Officer, Mr Thomas Liquard, as he settles into his new role.

Immuron Chairman Dr. Roger Aston commented on the role change:

"Mr. Anastasiou has been pivotal in supporting key programmes at Immuron for some time. Whether it be his network's original investment into Immuron 2.5 years ago, his driving of the direct to retailer sales model for Travelan in Australia, or his assistance to break into the US market with Travelan, his current dynamic approach in unlocking the significant opportunities for Australian biotech in the US, Peter has always supported Company growth activities with a view of establishing long term value creation for shareholders."

Mr. Anastasiou has kindly agreed to perform this increased level of duties for no additional remuneration.

Contact:

Dr Roger Aston
Non-Executive Chairman
Ph:+61 (0)3 9824 5254

Mr Peter Anastasiou
Deputy Executive Chairman
Ph:+61 (0)419 511 604

ABOUT IMMURON

Immuron Ltd (ASX:IMC) is a Microbiom company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The company currently markets Travelan® for the prevention of travellers' diarrhoea, its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH, and it has a preclinical immunotherapy pipeline targeting immune-related diseases with unmet needs.

Immuron's main scientific alliances are with Hadassah Medical Center (Israel), Monash University (Australia) and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) (Australia).